Fludarabine with intermediate-dose total body irradiation and PTCy for adults having allogeneic stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm, multicenter phase 2 trial of a conditioning regimen of fludarabine and intermediate-dose total body irradiation (TBI 800 cGy) followed by hematopoietic stem cell infusion and PTCy-based graft-versus-host disease prophylaxis. Fludarabine is given 30 mg/m2 daily on Days -6 to -2 and TBI is delivered as 800 cGy in four fractions over Days -2 and -1, with stem cell infusion on Day 0. GVHD prophylaxis consists of post-transplant cyclophosphamide 40 mg/kg on Days +3 and +4, then tacrolimus starting on Day +5 and mycophenolate mofetil from Days +5 to +35. The primary endpoint is one-year survival, with safety and transplant-related outcomes also monitored during follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients ages 18-65 years.
* Patients with a diagnosis of one of the following hematologic malignancies:
* Acute myeloid leukemia or chronic myeloid leukemia with no circulating blasts and less than 5% blasts in the bone marrow;
* Myelodysplastic syndrome with less than 5% blasts in the bone marrow by IHC or flow cytometry whichever is highest;
* Myeloproliferative neoplasms with less than 5% blast in the marrow and peripheral blood;
* Acute lymphoblastic leukemia in CR (CIBMTR criteria); or Lymphoma in CR (CIBMTR criteria).
* Patients who are eligible for allogeneic stem cell transplant per Transplant Program SOPs.
* Patients with a Karnofsky performance status (KPS) of ≥60%.
* Patients with adequate organ function defined by:

  * Cardiac: LVEF ≥50%
  * Pulmonary: DLCO ≥50% of predicted
  * Hepatic: Bilirubin ≤1.5x ULN, ALT/AST ≤2.5x ULN
  * Renal: Creatinine clearance ≥50 mL/min
* All participants of reproductive potential must use effective contraception following allogeneic hematopoietic stem cell transplantation (allo-HSCT), in accordance with guidelines from the American Society for Transplantation and Cellular Therapy (ASTCT), the FDA, and other expert bodies.
* For Male Participants:

  ○ Male participants must use effective contraception for at least 12 months after transplant, and longer if receiving immunosuppressive or cytotoxic medications. Chemotherapy and radiation can cause DNA damage to sperm, and even if fertility returns, mutations may persist for months. In cases where drugs such as mycophenolate mofetil (MMF) or lenalidomide are used, FDA guidance requires contraception for at least 90 days after discontinuation. Sperm cryopreservation should be offered prior to conditioning. Participants must avoid fathering a child during this time frame.15-17
* For Female Participants:

  * Female participants of childbearing potential are required to use highly effective contraception for a minimum of 12 to 24 months post-transplant, or longer if still receiving immunosuppressive or teratogenic therapy. For drugs such as MMF, sirolimus, or ruxolitinib, contraception must continue for 3 months after the last dose.
  * A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.15-17
* Patients with a suitable donor for allogeneic stem cell transplant defined by:

  * Matched sibling donors willing to donate mobilized peripheral blood (PBSC) or bone marrow (BM), meeting all institutional criteria for donation;
  * Unrelated donors at \>7/8 (i.e., mismatched at only one of the HLA-A, HLA-B, HLA-C, and HLA-DRB1 loci) willing to donate mobilized PBSC or BM, and medically eligible to donate cells according to National Marrow Donor Program criteria; or Related Haploidentical donors willing to donate PBSC or BM and meeting criteria for donation.
* Patients who are able to comply with follow-up visits and treatment plans.
* Patients who are able to give informed consent.

Exclusion Criteria:

* Hematopoietic cell transplantation comorbidity index above 3.
* Patients with a Karnofsky performance status (KPS) of \<60%.
* Patients with active infections or other contraindications for allogeneic stem cell transplant.
* Patients who are unable or unwilling to give informed consent.
* Patients who have received a prior allogeneic transplant.
* Patients who are unable to comply with follow-up visits and treatment plans.

Where it's running

• John Theurer Cancer Center at Hackensack University Medical Center
  Hackensack, New Jersey, United States Recruiting
• Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
  Washington D.C., District of Columbia, United States Not yet recruiting
• John Theurer Cancer Center at Jersey Shore University Medical Center
  Neptune City, New Jersey, United States Not yet recruiting

Study contacts

• Principal investigator: Michele Donato, MD — Hackensack Meridian Health
• Study coordinator: Oncology Clinical Research Referral Office
• Email: OncologyResearchReferral@hmhn.org
• Phone: 551-996-1777

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EGFR/HER2 dual-target CAR-NK cells for recurrent or metastatic HNSCC

  This trial tests an allogeneic CAR-NK cell therapy that targets EGFR and HER2 in adults with recurrent or metastatic head and neck cancer that express both biomarkers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07617805

• Bendamustine vs standard lymphodepletion before CAR-T in LBCL

  This trial tests whether bendamustine can replace the standard bendamustine-free lymphodepletion before CAR-T therapy in adults with large B-cell lymphoma who have had prior treatment.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Aarau and 8 other locations · NCT07593482

• Dual-target CAR-NK therapy against CLDN18.2 and HER2 for advanced stomach/GEJ cancer

  This trial will test an off-the-shelf, cord-blood-derived CAR-NK cell therapy that targets CLDN18.2 and HER2 in adults with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have progressed after at least two prior treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07551362

• Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma

  This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07492628

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• Intensity-modulated total marrow irradiation for high-risk blood cancers

  This study is testing a new type of radiation treatment combined with standard chemotherapy to see if it helps people with high-risk blood cancers feel better after receiving stem cell transplants.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT06802315

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.